Clinical trials: POAG
Treatment Outcome
Effect of Latanoprost on Optic Nerve Perfusion
46 eyes of 23 patients have been treated with topical Latanoprost 0.005 %. visual field was performed on all eyes. NFLT was measured using OCT. Radial peripapillary capillary (RPC) vascular density was measured using OCTA .
- Trial name
- NCT06629129
- Testing
- Latanoprost (0.005%)
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Zagazig University
Glaucoma Open-Angle Primary
OCTA Study of Choroidal Vasculature in Open Angle Glaucoma Patients
The aim of the present study was to examine and measure SFCT and CCVD using respectively EDI-OCT and OCTA in preperimetric and advanced glaucomatous eyes, in order to shed light on the vascular pathogenesis of glaucoma disease.
- Trial name
- NCT05455567
- Testing
- OCTA
- Where
- Italy
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Federico II University
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in subjects with Ocular Hypertension or Primary Open-Angle…
- Trial name
- NCT02829996
- Testing
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.
- Trial name
- NCT01637246
- Testing
- Any Fixed Combination Therapy
- Where
- Spain
- Volunteers
- 4,385 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- ANGEL-2 (NCT04742283)
- Testing
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- 41 sites in United States
- Volunteers
- 323 people
- Sponsor
- Santen Inc.
Glaucoma Open-Angle Primary, Ocular Hypertension
[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07662759
- Testing
- TFC-003, TFC-003-R1, TFC-003-R2+TFC-003-R3
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Kukje Pharma
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Trial name
- NCT00047541
- Testing
- Alcon Investigational Agent
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between…
- Trial name
- NCT00383019
- Testing
- Xalatan, Xalacom
- Where
- 54 sites in Japan
- Volunteers
- 300 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma
Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
- Trial name
- NCT04188015
- Testing
- 2.5mg ANX007, 5.0mg ANX007
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Annexon, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins
Glaucoma is a chronic optic neuropathy whose main modifiable risk factor is an abnormally elevated intraocular pressure. The aim of glaucoma treatment is to slow the progression of the disease by reducing intraocular pressure.
- Trial name
- NCT05039684
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Glaucoma, Open-Angle, Ocular Hypertension
A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness
Studies have shown that ocular surface disease (OSD) is common among patients with glaucoma with a prevalence of 50% or more. The percentage of affected patients appears to increase with increasing number of topical anti-glaucoma…
- Trial name
- NCT03204487
- Testing
- Tafluprost 15µg/ml
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Ordination Dr. Hommer
Open Angle Glaucoma, Ocular Hypertension
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.
- Trial name
- NCT06666855
- Testing
- DE-117B Eye Drops, Latanoprost
- Where
- 24 sites in China
- Volunteers
- 345 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Primary Open Angle Glaucoma
The Effects of Caffeinated Coffee on Intraocular Pressure
High intraocular pressure (IOP) is a known risk factor for developing primary open-angle glaucoma (POAG). There is controversy in the literature regarding the degree to which caffeine influences IOP, with some studies reporting…
- Trial name
- NCT01364207
- Testing
- Caffeinated Coffee, Decaffeinated Coffee
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Primary Open Angle Glaucoma
Reproducibility of RNFL and ONH Measurements in OAG With Heidelberg Spectralis SD-OCT Glaucoma Module Premium Edition
The purpose of this study is to assess and compare the repeatability of SD-OCT (Spectralis™ OCT, Version 6.0, Heidelberg Engineering, Germany) RNFL thickness measurements with a new software (glaucoma premium module) with the…
- Trial name
- NCT02247284
- Testing
- RNFL and BMO-MRW SD-OCT
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Primary Open Angle Glaucoma
Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery vs.
- Trial name
- NCT01841450
- Testing
- iStent, Cataract surgery
- Where
- 14 sites in United States
- Volunteers
- 360 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
OCTA in Patients With Primary Open-angle Glaucoma
Is to investigate retinal microvascular changes in primary open angle glaucoma patients using Optical Coherence Tomography Angiography.
- Trial name
- NCT06214676
- Testing
- OCT angiography
- Volunteers
- 30 people
- Sponsor
- Assiut University
Glaucoma, Open-angle, Ocular Hypertension
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the intraocular pressure(IOP)-lowering efficacy of a combination IOP-lowering therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00311389
- Testing
- Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution, Latanoprost 0.005%/Timolol 0.005% ophthalmic solution
- Where
- Belgium
- Volunteers
- 408 people
- Sponsor
- Alcon Research
Primary Open-angle Glaucoma
GORE Glaucoma Drainage Implant Clinical Study Dominican Republic
The objective of this early feasibility clinical study is to evaluate the safety and effectiveness of several different GORE Glaucoma Drainage Implant configurations in subjects with primary open-angle glaucoma that is…
- Trial name
- NCT05557058
- Testing
- Gore Glaucoma Device Implant (GORE GDI)
- Where
- Dominican Republic
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- W.L.Gore & Associates